Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9ULC4
UPID:
MCTS1_HUMAN
Alternative names:
Multiple copies T-cell malignancies
Alternative UPACC:
Q9ULC4; B4DGY2; Q502X6
Background:
Malignant T-cell-amplified sequence 1, also known as Multiple copies T-cell malignancies, plays a crucial role in cell cycle regulation, translation initiation, and DNA damage response. It enhances CDK4/6 activity, increases cyclin D1 levels, and promotes G1/S transition, contributing to faster cell proliferation. Additionally, it acts as a translation enhancer, up-regulating proteins involved in cell survival and growth, while also playing a role in lymphoid tumor development and breast cancer progression through various mechanisms including proteasome degradation of p53.
Therapeutic significance:
Understanding the role of Malignant T-cell-amplified sequence 1 could open doors to potential therapeutic strategies.